GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » Cash Flow from Operations

Daxor (DXR) Cash Flow from Operations : $-3.66 Mil (TTM As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Daxor Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Dec. 2023, Daxor's Net Income From Continuing Operations was $3.32 Mil. Its Depreciation, Depletion and Amortization was $0.00 Mil. Its Change In Working Capital was $0.11 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.00 Mil. And its Cash Flow from Others was $-4.21 Mil. In all, Daxor's Cash Flow from Operations for the six months ended in Dec. 2023 was $-0.78 Mil.


Daxor Cash Flow from Operations Historical Data

The historical data trend for Daxor's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daxor Cash Flow from Operations Chart

Daxor Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.11 -2.45 -2.76 -0.77 -3.66

Daxor Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.43 -0.49 -0.28 -2.87 -0.78

Daxor Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Daxor's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Daxor's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-3.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daxor  (NAS:DXR) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Daxor's net income from continuing operations for the six months ended in Dec. 2023 was $3.32 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Daxor's depreciation, depletion and amortization for the six months ended in Dec. 2023 was $0.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Daxor's change in working capital for the six months ended in Dec. 2023 was $0.11 Mil. It means Daxor's working capital increased by $0.11 Mil from Jun. 2023 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Daxor's cash flow from deferred tax for the six months ended in Dec. 2023 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Daxor's cash from discontinued operating Activities for the six months ended in Dec. 2023 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Daxor's asset impairment charge for the six months ended in Dec. 2023 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Daxor's stock based compensation for the six months ended in Dec. 2023 was $0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Daxor's cash flow from others for the six months ended in Dec. 2023 was $-4.21 Mil.


Daxor Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Daxor's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Daxor (DXR) Business Description

Traded in Other Exchanges
Address
109 Meco Lane, Oak Ridge, TN, USA, 37830
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Executives
Robert J Michel officer: CHIEF FINANCIAL OFFICER C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Michael Richard Feldschuh director 71 GRAND STREET #2, NEW YORK NY 10013
Joy S. Goudie director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers director DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Edward Feuer director 2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Soren Thompson officer: V.P./BUSINESS DEVELOPMENT 180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh director, officer: CHIEF SCIENTIFIC OFFICER DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh officer: President 615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh other: FOUNDER 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan officer: Corporate Secretary 259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe director 6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens director 200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson director P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom officer: Vice President 3244 BLACK FOX ROAD, WASHBURN TN 37888

Daxor (DXR) Headlines

From GuruFocus